Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


White House Plan B meeting?

This article was originally published in The Tan Sheet

Executive Summary

A copy of former FDA Commissioner Mark McClellan's appointment calendar while he headed the agency reveals that he met with White House staff in regard to Barr Labs' Rx-to-OTC switch application for Plan B, the Center for Reproductive Rights maintains. The group obtained a copy of the calendar through the discovery phase in its lawsuit against the FDA for delaying a decision on the switch. CRR told Magistrate Judge Viktor Pohorelsky May 11 that it will seek further details on McClellan's White House meeting during upcoming depositions in the case. McClellan is scheduled to be deposed June 13, while former commissioner Lester Crawford's deposition will take place May 24. CRR is requesting five additional depositions in the case, including those of Office of New Drugs Director John Jenkins and Office of Drug Evaluation III Deputy Director Julie Beitz. The group already has deposed Deputy Commissioner Janet Woodcock and CDER Director Steven Galson, and plans to make the transcripts public the week of May 15...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts